Patients with burn injury and inhalation injury are highly susceptible to infectious complications, including opportunistic pathogens, due to the loss of skin cover and mucosal damage of respiratory tract as well as the disruption of homeostasis. This case report, a 34-year-old man suffered critical burns, provides the first literature description of triple-impact immunoparalysis (critical burns, inhalation injury, and SARS-CoV-2 infection), leading to a lethal multifocal infection caused by several fungi including very rare environmental representatives Metschnikowia pulcherrima and Wickerhamomyces anomalus. The co-infection by these common environmental yeasts in a human is unique and has not yet been described in the literature. Importantly, our patient developed refractory septic shock and died despite targeted antifungal therapy including the most potent current antifungal agent-isavuconazole. It can be assumed that besides immunoparalysis, effectiveness of therapy by isavuconazole was impaired by the large distribution volume in this case. As this is a common situation in intensive care patients, routine monitoring of plasmatic concentration of isavuconazole can be helpful in personalization of the treatment and dose optimization. Whatmore, many fungal species often remain underdiagnosed during infectious complications, which could be prevented by implementation of new methods, such as next-generation sequencing, into clinical practice.
- MeSH
- antifungální látky * terapeutické užití MeSH
- COVID-19 * imunologie komplikace MeSH
- dospělí MeSH
- fatální výsledek MeSH
- koinfekce mikrobiologie farmakoterapie imunologie MeSH
- lidé MeSH
- mykózy farmakoterapie mikrobiologie imunologie diagnóza MeSH
- nitrily terapeutické užití MeSH
- popálení komplikace mikrobiologie MeSH
- pyridiny terapeutické užití MeSH
- Saccharomycetales genetika účinky léků imunologie MeSH
- SARS-CoV-2 imunologie MeSH
- sepse farmakoterapie mikrobiologie imunologie MeSH
- triazoly terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
There is only limited data on cytomegalovirus (CMV) prophylaxis with high-dose (HD) aciclovir after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis on a total of 179 patients who underwent their allo-HSCT with HD-aciclovir prophylaxis at our center. A clinically significant CMV infection (cs-CMVi) was observed in 56 (31%) cases with a median time of 49 (range 25-147) days after HSCT. A significantly higher CMV infection rate was observed in seropositive recipients with a seronegative donor (74%) compared to seropositive recipients with a seropositive donor, and seronegative recipients with seropositive and seronegative donors (24%, 18%, 7% respectively; p < 0.001). The CMV serostatus was the only significant risk factor for CMV infection in our analysis. CMV disease developed in three patients with CMV-related death in two cases. During HD-aciclovir prophylaxis, we did not observe any medical condition attributable to HD-aciclovir's adverse effects. Compared to published results, we observed a low incidence of cs-CMVi with HD-aciclovir prophylaxis in several patient subgroups, especially in seropositive recipients with a seropositive donor. With respect to the determined threshold, HD-aciclovir prophylaxis seems to have good efficacy in an intermediate cs-CMVi risk patients, but prospective randomized trials would be needed for definite conclusions.
- MeSH
- acyklovir terapeutické užití MeSH
- antivirové látky terapeutické užití MeSH
- cytomegalovirové infekce * etiologie prevence a kontrola farmakoterapie MeSH
- Cytomegalovirus MeSH
- lidé MeSH
- prospektivní studie MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The MLST scheme currently used for Enterococcus faecium typing was designed in 2002 and is based on putative gene functions and Enterococcus faecalis gene sequences available at that time. As a result, the original MLST scheme does not correspond to the real genetic relatedness of E. faecium strains and often clusters genetically distant strains to the same sequence types (ST). Nevertheless, typing has a significant impact on the subsequent epidemiological conclusions and introduction of appropriate epidemiological measures, thus it is crucial to use a more accurate MLST scheme. Based on the genome analysis of 1,843 E. faecium isolates, a new scheme, consisting of 8 highly discriminative loci, was created in this study. These strains were divided into 421 STs using the new MLST scheme, as opposed to 223 STs assigned by the original MLST scheme. The proposed MLST has a discriminatory power of D = 0.983 (CI95% 0.981 to 0.984), compared to the original scheme's D = 0.919 (CI95% 0.911 to 0.927). Moreover, we identified new clonal complexes with our newly designed MLST scheme. The scheme proposed here is available within the PubMLST database. Although whole genome sequencing availability has increased rapidly, MLST remains an integral part of clinical epidemiology, mainly due to its high standardization and excellent robustness. In this study, we proposed and validated a new MLST scheme for E. faecium, which is based on genome-wide data and thus reflects the tested isolates' more accurate genetic similarity. IMPORTANCE Enterococcus faecium is one of the most important pathogens causing health care associated infections. One of the main reasons for its clinical importance is a rapidly spreading resistance to vancomycin and linezolid, which significantly complicates antibiotic treatment of infections caused by such resistant strains. Monitoring the spread and relationships between resistant strains causing severe conditions represents an important tool for implementing appropriate preventive measures. Therefore, there is an urgent need to establish a robust method enabling strain monitoring and comparison at the local, national, and global level. Unfortunately, the current, extensively used MLST scheme does not reflect the real genetic relatedness between individual strains and thus does not provide sufficient discriminatory power. This can lead directly to incorrect epidemiological measures due to insufficient accuracy and biased results.
- Publikační typ
- abstrakt z konference MeSH
The Pseudomonas aeruginosa population has a nonclonal epidemic structure. It is generally composed of a limited number of widespread clones selected from a background of many rare and unrelated genotypes recombining at high frequency. Due to the increasing prevalence of nosocomial infections caused by multidrug-resistant/extensively drug-resistant (MDR/XDR) strains, it is advisable to implement infection control measures. Pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) are considered the gold standard methods in bacterial typing, despite being limited by cost, staff, and instrumental demands. Here, we present a novel mini-MLST scheme for P. aeruginosa rapid genotyping based on high-resolution melting analysis. Using the proposed mini-MLST scheme, 3,955 existing sequence types (STs) were converted into 701 melting types (MelTs), resulting in a discriminatory power of D = 0.993 (95% confidence interval [CI], 0.992 to 0.994). Whole-genome sequencing of 18 clinical isolates was performed to support the newly designed mini-MLST scheme. The clonal analysis of STs belonging to MelTs associated with international high-risk clones (HRCs) performed by goeBURST software revealed that a high proportion of the included STs are highly related to HRCs and have also been witnessed as responsible for serious infections. Therefore, mini-MLST provides a clear warning for the potential spread of P. aeruginosa clones recognized as MDR/XDR strains with possible serious outcomes. IMPORTANCE In this study, we designed a novel mini-MLST typing scheme for Pseudomonas aeruginosa. Its great discriminatory power, together with ease of performance and short processing time, makes this approach attractive for prospective typing of large isolate sets. Integrating the novel P. aeruginosa molecular typing scheme enables the development and spread of MDR/XDR high-risk clones to be investigated.
- MeSH
- buněčné klony MeSH
- genotyp MeSH
- lidé MeSH
- molekulární epidemiologie metody MeSH
- multilokusová sekvenční typizace MeSH
- prospektivní studie MeSH
- pseudomonádové infekce * epidemiologie mikrobiologie MeSH
- Pseudomonas aeruginosa * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Bacterial genotyping is a crucial process in outbreak investigation and epidemiological studies. Several typing methods such as pulsed-field gel electrophoresis, multilocus sequence typing (MLST) and whole genome sequencing are currently used in routine clinical practice. However, these methods are costly, time-consuming and have high computational demands. An alternative to these methods is mini-MLST, a quick, cost-effective and robust method based on high-resolution melting analysis. Nevertheless, no standardized approach to identify markers suitable for mini-MLST exists. Here, we present a pipeline for variable fragment detection in unmapped reads based on a modified hybrid assembly approach using data from one sequencing platform. RESULTS: In routine assembly against the reference sequence, high variable reads are not aligned and remain unmapped. If de novo assembly of them is performed, variable genomic regions can be located in created scaffolds. Based on the variability rates calculation, it is possible to find a highly variable region with the same discriminatory power as seven housekeeping gene fragments used in MLST. In the work presented here, we show the capability of identifying one variable fragment in de novo assembled scaffolds of 21 Escherichia coli genomes and three variable regions in scaffolds of 31 Klebsiella pneumoniae genomes. For each identified fragment, the melting temperatures are calculated based on the nearest neighbor method to verify the mini-MLST's discriminatory power. CONCLUSIONS: A pipeline for a modified hybrid assembly approach consisting of reference-based mapping and de novo assembly of unmapped reads is presented. This approach can be employed for the identification of highly variable genomic fragments in unmapped reads. The identified variable regions can then be used in efficient laboratory methods for bacterial typing such as mini-MLST with high discriminatory power, fully replacing expensive methods such as MLST. The results can and will be delivered in a shorter time, which allows immediate and fast infection monitoring in clinical practice.
Recently, nanopore sequencing has come to the fore as library preparation is rapid and simple, sequencing can be done almost anywhere, and longer reads are obtained than with next-generation sequencing. The main bottleneck still lies in data postprocessing which consists of basecalling, genome assembly, and localizing significant sequences, which is time consuming and computationally demanding, thus prolonging delivery of crucial results for clinical practice. Here, we present a neural network-based method capable of detecting and classifying specific genomic regions already in raw nanopore signals-squiggles. Therefore, the basecalling process can be omitted entirely as the raw signals of significant genes, or intergenic regions can be directly analyzed, or if the nucleotide sequences are required, the identified squiggles can be basecalled, preferably to others. The proposed neural network could be included directly in the sequencing run, allowing real-time squiggle processing.
- Publikační typ
- časopisecké články MeSH
Cryptococcal superinfection is a rare but potentially fatal complication, especially if its detection and subsequent treatment are delayed. Histopathological findings of pulmonary parenchyma from a deceased patient with these complications were acquired. Quite interestingly, only a minimal inflammatory reaction could be seen in an individual with no previously known immune suppression, indicating a disturbance of the immune system. This finding was well in concordance with the described changes in cellular immunity in COVID-19. We report the case of a 60 year old male with critical coronavirus disease 2019 (COVID-19) complicated by cryptococcal pneumonia and multiorgan failure. Both X-ray and CT scans revealed lung infiltrates corresponding with COVID-19 infection early after the onset of symptoms. Despite receiving standard treatment, the patient progressed into multiple organ failure, requiring mechanical ventilation, circulatory support, and haemodialysis. Cryptococcus neoformans was detected by subsequent BAL, and specific antifungal treatment was instituted. His clinical status deteriorated despite all treatment, and he died of refractory circulatory failure after 21 days from hospital admission. Histopathological findings confirmed severe diffuse alveolar damage (DAD) caused by COVID-19 and cryptococcal pneumonia. Timely diagnosis of cryptococcal superinfection may be challenging; therefore, PCR panels detecting even uncommon pathogens should be implemented while taking care of critical COVID-19 patients.
- Publikační typ
- časopisecké články MeSH
x
x
- MeSH
- diagnostické techniky molekulární klasifikace MeSH
- mikrobiální genetika metody MeSH
- nanoporové sekvenování metody MeSH
- sekvenční analýza DNA metody MeSH
- sekvenování celého genomu klasifikace metody MeSH
- techniky typizace bakterií metody MeSH
- vysoce účinné nukleotidové sekvenování * klasifikace metody přístrojové vybavení MeSH
- Publikační typ
- práce podpořená grantem MeSH
- přehledy MeSH
Reaktivace cytomegaloviru (CMV) po alogenní transplantaci krvetvorných buněk s její následnou antivirotickou léčbou je významnou komplikací vedoucí ke zvýšené morbiditě a mortalitě těchto pacientů. V rámci prevence rozvoje CMV nemoci byl dosud nejrozšířenější preemptivní přístup spočívající ve frekventní monitoraci CMV virémie s časným zahájením preemptivní antivirotické léčby v případě známek CMV reaktivace. Tento přístup na jedné straně vede k nízké incidenci CMV nemoci, na druhé straně však procento CMV reaktivací s nutností nasazení preemptivní léčby zůstává vysoké, přičemž již samotná reaktivace vede ke zvýšení morbidity a nerelapsové mortality. Letermovir představuje nové virostatikum s účinkem na cytomegalovirus, které má schválení SÚKL (Státního ústavu pro kontrolu léčiv) u CMV séropozitivních pacientů po alogenní transplantaci krvetvorných buněk. V registrační, randomizované, placebem kontrolované studii, jež vyústila v uvedení letermoviru do klinické praxe, byl prokázán pozitivní vliv na snížení incidence klinicky signifikantní CMV infekce a zároveň pokles nerelapsové mortality ve srovnání s placebem, především u pacientů v nejvyšším riziku CMV onemocnění. Ačkoli je letermovir v primární profylaxi CMV po alogenní transplantaci krvetvorby již běžné užíván, s jeho použitím se pojí řada nevyjasněných otázek, jako jsou optimální délka trvání profylaxe nebo jeho použití v sekundární profylaxi či preemptivní léčbě CMV reaktivace. Následující práce shrnuje v současnosti dostupná literární data týkající se použití letermoviru u pacientů po alogenní transplantaci krvetvorných buněk.
Cytomegalovirus (CMV) reactivation after allogeneic haematopoietic stem cell transplantation and its subsequent antiviral treatment is a significant complication leading to increased morbidity and mortality in these patients. Frequent monitoring of CMV viremia with early pre-emptive antiviral treatment in case of CMV reactivation represents the most widely used option to date for preventing CMV disease. While this approach leads to a low incidence of CMV disease, the percentage of CMV reactivations requiring pre-emptive therapy remains high and increased morbidity and non-relapse mortality are thus associated with CMV reactivation per se. Letermovir is a new antiviral drug with anti-CMV activity approved for use in CMV seropositive patients after allogeneic hematopoietic stem cell transplantation. A randomized, placebo-controlled study that led to the introduction of letermovir into clinical practice demonstrated a positive effect in reducing the incidence of clinically significant CMV infection as well as non-relapse mortality compared to placebo, especially in patients at high risk of CMV disease. Although it is already commonly used in primary CMV prophylaxis after allogeneic hematopoietic transplantation, its use is associated with certain unresolved issues such as the optimal duration of prophylaxis or its use in secondary prophylaxis or pre-emptive treatment of CMV reactivation. The following article summarizes currently available data on the use of letermovir in patients after allogeneic hematopoietic stem cell transplantation.
- Klíčová slova
- letermovir,
- MeSH
- acetáty farmakologie terapeutické užití MeSH
- cytomegalovirové infekce * prevence a kontrola MeSH
- homologní transplantace MeSH
- klinické zkoušky jako téma MeSH
- léková rezistence MeSH
- lidé MeSH
- preexpoziční profylaxe MeSH
- rizikové faktory MeSH
- transplantace kostní dřeně * MeSH
- Check Tag
- lidé MeSH
